Ownership and insider activity for Merck & Co., Inc. (MRK): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes.
Price
| Price | $139.54 |
| Market Cap | $344.6B |
| Exchange | NYSE |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-30 | Seidman Christine E | A-Award | 55 | |
| 2026-09-30 | Karsanbhai Surendralal Lanca | A-Award | 111 | |
| 2026-09-30 | Coe Mary Ellen | A-Award | 206 | |
| 2026-09-01 | Gupta Gaurav K | |||
| 2027-08-07 | Gupta Gaurav K | 19,443 | ||
| 2026-08-13 | Guindo Chirfi | S-Sale | 10,000 | $1.4M |
| 2026-08-12 | Zachary Jennifer | M-Exempt | 13,433 | $1.1M |
| 2026-08-12 | Zachary Jennifer | M-Exempt | 41,494 | $4.9M |
| 2026-08-12 | Zachary Jennifer | S-Sale | 80,315 | $10.7M |
| 2026-08-12 | Zachary Jennifer | M-Exempt | 41,494 | $4.9M |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.51B | $6.09B | $7.96B | $9.68B | $8.05B | $8.10B | $12.69B | $6.84B | $13.24B | $14.56B |
| Short-term Investments | $7.83B | $2.41B | $899.0M | $774.0M | 0 | 0 | $498.0M | $252.0M | $447.0M | 0 |
| Receivables | $7.02B | $6.87B | $7.07B | $6.78B | $6.80B | $9.23B | $9.45B | $10.35B | $10.28B | $12.68B |
| Inventory | $4.87B | $5.10B | $5.44B | $5.98B | $5.55B | $5.95B | $5.91B | $6.36B | $6.11B | $6.66B |
| Total Current Assets | $30.61B | $24.77B | $25.88B | $27.48B | $27.76B | $30.27B | $35.72B | $32.17B | $38.78B | $43.52B |
| Property, Plant & Equipment | $12.03B | $12.44B | $13.29B | $15.05B | $17.00B | $19.28B | $21.42B | $23.05B | $23.78B | $26.82B |
| Goodwill | $18.16B | $18.28B | $18.25B | $19.43B | $18.88B | $21.26B | $21.20B | $21.20B | $21.67B | $21.58B |
| Intangible Assets | $17.30B | $14.18B | $13.10B | $14.20B | $14.10B | $22.93B | $20.27B | $18.01B | $16.37B | $26.68B |
| Total Assets | $95.38B | $87.87B | $82.64B | $84.40B | $91.59B | $105.69B | $109.16B | $106.67B | $117.11B | $136.87B |
| Accounts Payable | $2.81B | $3.10B | $3.32B | $3.74B | $4.33B | $4.61B | $4.26B | $3.92B | $4.08B | $4.40B |
| Short-term Debt | $568.0M | $3.06B | $5.31B | $3.61B | $6.43B | $2.41B | $1.95B | $1.37B | $2.65B | $2.88B |
| Total Current Liabilities | $17.20B | $18.61B | $22.21B | $22.22B | $27.33B | $23.87B | $24.24B | $25.69B | $28.42B | $28.33B |
| Long-term Debt | $24.27B | $21.35B | $19.81B | $22.74B | $25.36B | $30.69B | $28.75B | $33.68B | $34.46B | $46.75B |
| Total Liabilities | $55.07B | $53.30B | $55.76B | $58.40B | $66.18B | $67.44B | $63.10B | $69.04B | $70.73B | $84.20B |
| Retained Earnings | $44.13B | $41.35B | $42.58B | $46.60B | $47.36B | $53.70B | $61.08B | $53.90B | $63.07B | $73.08B |
| Total Equity | $40.09B | $34.34B | $26.70B | $25.91B | $25.32B | $38.18B | $45.99B | $37.58B | $46.31B | $52.61B |
| Total Debt | $24.84B | $24.41B | $25.11B | $27.35B | $33.42B | $34.63B | $31.98B | $36.27B | $38.27B | $50.53B |
| Net Debt | $10.50B | $15.91B | $16.25B | $16.90B | $25.37B | $26.54B | $18.79B | $29.18B | $24.58B | $35.97B |
| Working Capital | $13.41B | $6.15B | $3.67B | $5.26B | $437.0M | $6.39B | $11.48B | $6.47B | $10.36B | $15.19B |
Financial Health
| Debt / Equity | 1.29 |
| Current Ratio | 1.32 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 3.80 |
Profitability
| Return on Equity | 6.60% |
| Return on Invested Capital | 5.62% |
| Return on Assets | 2.44% |
| Gross Margin | 75.38% |
| Operating Margin | 16.65% |
| Net Margin | 4.78% |
Related companies: ABT · AMGN · AZN · GILD · GSK · NVO · NVS
Explore sector: Healthcare · Drug Manufacturers - General
More sections of MRK: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks